Ehave Signs Licensing Agreement to Enhance its Telemedicine Platform
MIAMI, Sept. 04, 2020 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced it is entering into a licensing agreement with a telemedicine solutions provider from a single integrated platform. Under the terms of the agreement Ehave will provide its patients access to the telemedicine solutions provider’s complete suite of single integrated platform. This online platform offers a complete suite of telemedicine solutions allowing members to request an online consultation, to obtain a second medical opinion in as fast as 48 hours or access their complete medical history anytime, anywhere from their computer or mobile device. Members will be able to share their medical history with select family members and providers to improve treatment outcomes and cultivate better care, helping to save, money, time and lives.
Separately, Ehave, Inc. has recently finalized an agreement with Burst IQ for 1 TB of transactions on the BlockChain per month. Ehave plans to work with Burst IQ to develop video surveys with analysis for both COVID-19 and people taking psychedelics. The questions are onscreen and allow the participant to answer them as they go through the video.Ehave is also expecting the Hospital for Sick Children in Toronto (“SickKids”) to start up its trials for MegaTeam assessment and rehabilitation products after COVID-19. Shareholders and other interested parties can read more at https://www.ehave.com/adhd-pilot-program.Ehave, Inc. CEO Ben Kaplan said, “As we move toward the psychedelic space, we are looking to advance the ways individuals can control their medical history. We expect to release more information regarding our longer term plans at a later time.”About Ehave, Inc.Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.Forward-Looking Statement DisclaimerThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.Media and Investors Relations, please contact:Gabe RodriguezPhone: (623) 261-9046Email: firstname.lastname@example.org